Cargando…

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records

On the basis of the results from CLEOPATRA, pertuzumab plus trastuzumab and chemotherapy is the first-line standard of care for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). However, discrepancies have been reported between clinical trial and real-world out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polito, Letizia, Shim, Jinjoo, Hurvitz, Sara A., Dang, Chau T., Knott, Adam, Du Toit, Yolande, Restuccia, Eleonora, Sanglier, Thibaut, Swain, Sandra M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2023
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337715/ https://www.ncbi.nlm.nih.gov/pubmed/37167571 http://dx.doi.org/10.1200/OP.22.00565

Ejemplares similares

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
por: Krop, Ian E., et al.
Publicado: (2022)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

A Rare Case of Pertuzumab-Induced Toxic Epidermal Necrolysis
por: Mohamed Jiffry, Mohamed Zakee, et al.
Publicado: (2023)

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
por: Swain, Sandra M., et al.
Publicado: (2022)

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
por: Perez, Edith A., et al.
Publicado: (2017)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
por: Ligorio, Francesca, et al.
Publicado: (2021)

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial
por: Iyengar, Neil M., et al.
Publicado: (2019)

Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results
por: Andersson, Michael, et al.
Publicado: (2017)

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
por: Swain, S M, et al.
Publicado: (2018)

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States
por: Sussell, Jesse A., et al.
Publicado: (2023)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
por: Zhang, Jing, et al.
Publicado: (2017)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
por: Pohlmann, Paula R., et al.
Publicado: (2022)

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
por: Lamond, Nathan WD, et al.
Publicado: (2014)

Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan
por: OSAKO, TOMOFUMI, et al.
Publicado: (2015)

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
por: Gamucci, Teresa, et al.
Publicado: (2018)

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Pertuzumab in Metastatic Breast Cancer
por: Patel, Rachana, et al.
Publicado: (2012)

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
por: Tabernero, Josep, et al.
Publicado: (2022)

Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
por: Perez, Edith A., et al.
Publicado: (2016)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Optimal use of taxanes in metastatic breast cancer
por: King, K.M., et al.
Publicado: (2009)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study
por: Dorand, R. Dixon, et al.
Publicado: (2023)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3igsmptjg9u5imdiaoc4qjb3io